Loading institutional data...
Loading institutional data...
Institutional ownership roughly stable: -0.31% change quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
3/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$8M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 9 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -170%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 9 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $88000 covers the $0 due within a year 88000.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Interest last disclosed in FY2020 (no longer broken out).
Cash of $88000 fully covers short-term debt of $0.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $819K 100.0% | $420K 100.0% | $442K 100.0% | $14K 100.0% | $22K 100.0% | $4.4M 100.0% | $7.2M 100.0% | $6.3M 100.0% | $5.9M 100.0% |
| Cost of Revenue | $63K 7.7% | $42K 10.0% | $30K 6.8% | $161K 1150.0% | $1.6M 7090.9% | $5.5M 124.4% | $8.8M 122.9% | $4.2M 67.2% | $4.2M 71.0% |
| Gross Profit | $756K 92.3% | $378K 90.0% | $412K 93.2% | -$147K -1050.0% | -$1.5M -6990.9% | -$1.9M -43.4% | -$1.7M -22.9% | $2.1M 32.8% | $1.7M 29.0% |
| Research & Development | — | $272K 64.8% | $475K 107.5% | $6.4M 45657.1% | $12.3M 55695.5% | $9.0M 203.3% | $4.5M 62.9% | $2.8M 44.4% | $4.5M 77.0% |
| Selling, General & Admin | $12.1M 1474.4% | $11.3M 2702.1% | $17.1M 3873.8% | $16.3M 116071.4% | $15.5M 70340.9% | $24.5M 556.9% | $51.5M 716.1% | $30.4M 486.4% | $14.9M 254.6% |
| Total Operating Expenses | $21.9M 2673.9% | $11.6M 2766.9% | $78.5M 17767.2% | $26.8M 191528.6% | $27.7M 126036.4% | $33.5M 760.2% | $56.1M 779.0% | $33.2M 530.8% | $19.5M 331.6% |
| Operating Income | -$21.1M -2581.6% | -$11.2M -2676.9% | -$78.1M -17674.0% | -$27.0M -192578.6% | -$29.3M -133027.3% | -$35.4M -803.7% | -$57.7M -801.9% | -$31.2M -498.0% | -$17.8M -302.6% |
| Interest Expense | — | — | — | — | — | $108K 2.5% | $250K 3.5% | $14K 0.2% | $4K 0.1% |
| Interest & Investment Income | $34K 4.2% | $81K 19.3% | $347K 78.5% | $0 0.0% | — | $129K 2.9% | $1.0M 14.4% | $352K 5.6% | — |
| Other Income (Expense), net | $1.6M 200.0% | -$2.3M -537.9% | $7.5M 1707.5% | $99K 707.1% | $2.0M 9131.8% | $88K 2.0% | $788K 10.9% | $338K 5.4% | -$4K -0.1% |
| Pretax Income | -$19.5M -2381.6% | -$13.5M -3214.8% | -$70.6M -15966.5% | -$26.9M -191871.4% | -$27.3M -123895.5% | -$35.3M -801.7% | -$56.9M -791.0% | -$30.8M -492.6% | -$17.8M -302.6% |
| Income Tax Expense | -$1.8M -221.0% | $3.1M 747.9% | $0 0.0% | $3K 21.4% | $4K 18.2% | $7K 0.2% | $15K 0.2% | $10K 0.2% | $1K 0.0% |
| Net Income | -$17.2M -2098.0% | -$16.6M -3962.6% | -$70.6M -15966.5% | -$26.9M -191892.9% | -$25.1M -113954.5% | -$36.0M -818.3% | -$57.0M -791.2% | -$30.8M -492.8% | -$17.8M -302.6% |
| Per Share | |||||||||
| EPS (Basic) | $-15.90 | $-126.91 | $-129.88 | $-25.98 | $-248.22 | — | — | — | — |
| EPS (Diluted) | — | — | — | $-25.98 | $-248.22 | — | — | — | — |
| Weighted Avg Shares (Basic) | 1.1M | 172K | 550K | 1.0M | 101K | — | — | — | — |
| Weighted Avg Shares (Diluted) | — | — | — | 1.0M | 101K | — | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 12 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
Nothing notable to watch.
Where each multiple sits in its own 8-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 8-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 67.2 | 122.9 | 124.4 | 7090.9 | 1150.0 | 6.8 | 10.0 | 7.7 |
| Gross Profit | 32.8 | -22.9 | -43.4 | -6990.9 | -1050.0 | 93.2 | 90.0 | 92.3 |
| R&D | 44.4 | 62.9 | 203.3 | 55695.5 | 45657.1 | 107.5 | 64.8 | — |
| SG&A | 486.4 | 716.1 | 556.9 | 70340.9 | 116071.4 | 3873.8 | 2702.1 | 1474.4 |
| Operating Income | -498.0 | -801.9 | -803.7 | -133027.3 | -192578.6 | -17674.0 | -2676.9 | -2581.6 |
| Income Tax | 0.2 | 0.2 | 0.2 | 18.2 | 21.4 | 0.0 | 747.9 | -221.0 |
| Net Income | -492.8 | -791.2 | -818.3 | -113954.5 | -191892.9 | -15966.5 | -3962.6 | -2098.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on VTAK: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| VTAK | $278233 | — | — | 0.3× | 95.0% | 92.3% | -2098% | -244% | -170% | -0.2× | 12 |
Peers = companies sharing VTAK's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.